Soleno Therapeutics, INC.

Soleno is focused on development of novel therapeutics for treatment of rare diseases.

Based in CA

🤖

AI Overview

With $550K in lobbying spend across 13 quarterly filings, Soleno Therapeutics, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2023 to 2025.

$550K
Total Spend
3
Years Active
1
Firms Hired
5
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2023$140K
2024$210K
2025$200K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues

  • Rare disease drug development Orphan Drug Act Orphan Drug Tax Credit Priority Review Voucher Expedited approval pathways Patient-focused Drug Development
  • H.R.2471 - Consolidated Appropriations Act, 2022 (117th)
  • Senate HELP Minority- FDA Modernization H.R. 2471 - Consolidated Appropriations Act, 2022 (117th) H.R. 1350 - Camerons Law S. 1906 - Promising Pathway Act
  • H.R.4408/S.1906 - Promising Pathway Act H.R. 6888/S. 4071 - Helping Experts Accelerate Rare Treatments (HEART) Act [117th Congress] H.R. 2471 - Consolidated Appropriations Act, 2022 [117th Congress]

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.